ストックスクリーナーアプリを入手
44.65
3.85%
-1.8325
Maze Therapeutics Inc (MAZE) 最新ニュース
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside - TipRanks
MAZE: Lead kidney and metabolic disease programs advance toward pivotal data with strong financial backing - TradingView
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest - MarketBeat
Aug Update: What analysts say about Maze Therapeutics Inc stockWeekly Profit Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Pullback Watch: Is Iveda Solutions Inc a good ESG investmentMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Innovator with a 10.77% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Maze Therapeutics Inc CEO set for TD Cowen Health Care event - Traders Union
MAZE Technical Analysis & ETF Price Forecast - Intellectia AI
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst - TipRanks
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech With A 9.78% Upside Potential - DirectorsTalk Interviews
Is Maze Therapeutics Inc. forming bullish engulfing patterns2025 Year in Review & Stepwise Entry and Exit Trade Signals - mfd.ru
Latest MAZE ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma
Zifo and Maze Therapeutics Partner to Power Precision Medicine - The Malaysian Reserve
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - AOL.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Earnings Recap: How liquid is Maze Therapeutics Inc stockQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - The Motley Fool
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN
MAZE Should I Buy - Intellectia AI
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit - MarketBeat
Frazier Life Sciences discloses Maze Therapeutics (MAZE) 9% ownership and warrants cap - Stock Titan
Bull Bear: What analysts say about Maze Therapeutics Inc stockGlobal Markets & Weekly High Return Opportunities - baoquankhu1.vn
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Sahm
IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook on Strong Buy Ratings and 12.50% Upside Potential - DirectorsTalk Interviews
Maze Therapeutics Secures New $200 Million Loan Facility - The Globe and Mail
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock - Defense World
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - AOL.com
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock - MarketBeat
Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook And 9.88% Potential Upside - DirectorsTalk Interviews
Washington University Takes Position in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com Canada
Equities Analysts Set Expectations for MAZE FY2030 Earnings - MarketBeat
Maze Therapeutics Rings the Closing Bell - Nasdaq
Maze Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Raised to "Hold" at Wall Street Zen - MarketBeat
4.16%
0.71%
大文字化:
|
ボリューム (24 時間):